Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

What is Moderna Inc.?

Moderna (MRNA) is a leading biotechnology company known for its advancements in mRNA technology, particularly in the development of vaccines. The stock had a bearish movement today amidst recent market volatility.

Why is Moderna Inc. going down?

MRNA stock is down 5.4% on May 13, 2026 19:57

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna stock (US60770K1034): Ranked #1 on TIME's 2026 Most Impactful Companies

Moderna has been ranked #1 on TIME's 2026 World's Most Impactful Companies list, recognizing its significant contributions to mRNA technology and public health, despite a recent 3% drop in share price. This ranking follows the company's Q1 earnings report, which indicated an EPS of ($3.40). The article provides an overview of Moderna's business model, key revenue drivers, competitive position in the biotech sector, and its relevance for US investors.

https://www.ad-hoc-news.de/boerse/news/ueberblick/moderna-stock-us60770k1034-ranked-1-on-time-s-2026-most-impactful/69325233

Dominari Holdings reports Q1 revenue up 395% to $35.8 million

Dominari Holdings Inc. (NASDAQ:DOMH) reported a substantial increase in Q1 revenue, reaching $35.8 million, up 395% from the previous year. Underwriting revenues surged by 488% to $32.9 million, and the company also authorized a special cash dividend of approximately $9 million ($0.31 per share). Despite remaining unprofitable with an EPS of -$1.57 over the trailing twelve months, the company's significant dividend yield is highlighted for income-focused investors.

https://www.investing.com/news/company-news/dominari-holdings-reports-q1-revenue-up-395-to-358-million-93CH-4684366

Moderna Stock Has Rallied. It’s the Ultimate Pandemic Hedge.

Moderna's stock has rallied as investors view it as a pandemic hedge, despite facing reduced demand for its Covid vaccines and a challenging regulatory landscape. The company is at a crossroads, with some betting on a "hantavirus trade" to revive its previous success.

https://www.barrons.com/articles/moderna-stock-price-covid-hantavirus-351d4e2f

Sinovac Foundation donates 3.83 lakh doses of polio vaccine to Bangladesh

The Sinovac Foundation, a subsidiary of China's Sinovac Biotech Limited, has donated 3.83 lakh doses of polio vaccine to Bangladesh. This donation aims to bolster the Bangladesh government's Expanded Programme on Immunization (EPI) and support global polio eradication efforts. Health Minister Sardar Md. Sakhawat Husain expressed gratitude to China, highlighting the challenge of managing various diseases despite successful measles vaccination campaigns.

https://www.bssnews.net/news/386574

Denison Mines earnings missed by $0.08, revenue topped estimates

Denison Mines (NYSE: DNN) reported first-quarter earnings per share (EPS) of $-0.0948, missing analyst estimates by $0.08, despite revenue of $806.74K surpassing the consensus estimate. The company's stock price closed at $3.70, showing a decline of -2.12% over the last three months but a significant increase of 145.03% in the past year. InvestingPro rates Denison Mines' financial health as "weak performance."

https://www.investing.com/news/earnings/denison-mines-earnings-missed-by-008-revenue-topped-estimates-4683142

Trending Today

0x ($ZRX) Crypto Forecast: Down 9.1% Today

Chainlink ($LINK) Crypto Forecast: Down 5.3% Today

Solana ($SOL) Crypto Forecast: Down 5.1% Today

QTUM ($QTUM) Crypto Forecast: Down 5.3% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

Waters Corporation ($WAT) Stock Forecast: Down 5.0% Today

Aramark ($ARMK) Stock Forecast: Up 5.1% Today

NRG Energy Inc. ($NRG) Stock Forecast: Down 5.1% Today

Accenture plc Class A (Ireland) ($ACN) Stock Forecast: Down 6.6% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 5.3% Today

Moderna Inc. Price History

07.04.2026 - MRNA Stock was up 8.5%

• The surge in Moderna's stock is likely linked to positive updates regarding its mRNA-1010 candidate for seasonal influenza, which displayed superior efficacy in Phase 3 trials compared to traditional flu vaccines.
• The announcement of the vaccine's robust relative efficacy, particularly in adults over 65 and overall, against different influenza strains, likely bolstered investor faith in Moderna's vaccine portfolio.
• The anticipation surrounding the potential FDA verdict on the vaccine by August 5, 2026, coupled with ongoing evaluations by regulatory bodies in various nations, contributed to the optimistic outlook on Moderna's influenza vaccine, fueling the stock's bullish movement.

12.04.2026 - MRNA Stock was down 6.7%

• Moderna (MRNA) faced a downturn today, potentially influenced by profit-taking following recent positive developments.
• The dip in Merck's stock value, attributed to a one-time charge stemming from an acquisition and a setback in its pipeline, may have impacted overall sentiments towards biotech equities, including Moderna.
• Investor attention could have shifted towards companies like Halozyme Therapeutics (HALO) with optimistic revenue projections, prompting a brief sell-off in Moderna shares.
• Market influencers within the biotech domain embracing cutting-edge technologies such as AI might have diverted focus away from Moderna, contributing to its bearish performance today.

08.04.2026 - MRNA Stock was up 12.8%

• Following the release of positive Phase 3 flu vaccine data, Moderna's stock showed a strong bullish trend. The data highlighted the efficacy of mRNA-1010 compared to standard flu vaccines in older adults.
• Moderna's stock rebounded after favorable earnings and a successful performance in 2026. This reflected investor confidence in the company's mRNA platform and its potential for revenue growth beyond the realm of COVID-19 vaccines.
• The positive Phase 1 data announcement for Moderna's mRNA hantavirus vaccine further boosted investor confidence. This demonstrated how Moderna's mRNA technology can effectively target different viral diseases.
• Moderna's recent bullish market movement can be linked to its successful vaccine developments, robust earnings, and the confirmation of its mRNA platform's potential to address a broad array of health issues.

08.04.2026 - MRNA Stock was up 6.2%

• The strong bullish movement of Moderna's stock today is due to the positive Phase 1 data release for its mRNA hantavirus vaccine, showcasing its versatility in targeting different viral diseases and renewing investor confidence in the company's mRNA pipeline.
• Moderna's shares rebounded following positive quarterly earnings and a strong 2026 performance, with investors considering the transition from pandemic-driven revenues to a broader product portfolio.
• Investor sentiment received a boost as Gateway Investment Advisers LLC significantly increased its stake in Moderna, especially with promising Phase 3 results for the company's seasonal flu vaccine, mRNA-1010.
• Market sentiment towards Moderna was positive despite developments from other biotech companies like CytomX Therapeutics and Arrowhead Pharmaceuticals, underscoring the market's focus on specific companies' developments and performance.

08.04.2026 - MRNA Stock was up 13.7%

• Moderna's bullish movement can be attributed to the positive Phase 3 flu vaccine data for its mRNA-1010 candidate, showcasing superior efficacy compared to standard flu vaccines.
• The SEC filing indicating a proposed sale of securities might have initially caused some uncertainty but was overshadowed by the promising vaccine results.
• The positive news from Regeneron Pharmaceuticals receiving FDA approval for the first neurosensory gene therapy could have boosted overall investor sentiment in the biotech sector, benefiting Moderna as well.
• Moderna's potential for building durable revenue beyond COVID-19 vaccines with upcoming FDA approvals could have further fueled investor optimism, driving the stock's bullish momentum.

08.04.2026 - MRNA Stock was up 11.8%

• Ongoing research into hantavirus vaccines by Moderna may have boosted investor confidence in the company's ability to address emerging infectious diseases, contributing to the bullish movement.
• A SEC filing indicating a proposed sale of securities by Moderna may have initially caused some uncertainty among investors, but the overall positive sentiment surrounding the company's vaccine development efforts likely overshadowed this news.
• The broader positive sentiment in the biotechnology sector, as evidenced by Cboe Global Markets hitting an all-time high, could have also positively influenced Moderna's stock performance today.
• Moderna's focus on advancing its vaccine pipeline, as seen in the update on its RSV and H5 flu vaccine trial, may have further reinforced investor optimism in the company's long-term growth prospects, contributing to the bullish market movement.

07.04.2026 - MRNA Stock was down 6.1%

• The stock of Moderna faced a downward trend today despite the positive developments related to its mRNA technology and vaccine progress.
• Following the release of robust Q1 outcomes and promising data on its COVID vaccine, Novavax's stock saw a significant increase, potentially shifting investor focus away from Moderna.
• Concerns arose within the biotech sector after the Phase 3 trial failure of Lipocine's LPCN 1154 for postpartum depression, impacting Moderna's stock.
• Internal disagreements at the FDA, exemplified by Sanofi requesting the removal of Tzield from the CNPV program, might have instigated uncertainty over regulatory procedures for companies like Moderna, influencing the downward movement.

11.04.2026 - MRNA Stock was down 7.7%

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

11.04.2026 - MRNA Stock was down 5.1%

• Moderna's stock increased by 6% today, surpassing other vaccine companies like Pfizer and Novavax. This was driven by heightened interest in its Hantavirus vaccine after a recent outbreak on a cruise ship and robust Q1 2026 revenue results. However, concerns about returning to pre-COVID revenue levels and ongoing losses might have led to profit-taking and a bearish trend in the stock.
• Moderna's wide-ranging mRNA platform, along with upcoming Phase 3 study outcomes, continues to support its positive market momentum despite the recent decline.
• The overall market sentiment towards biotech companies and uncertainties about future revenue sustainability post-COVID may have played a role in today's downward movement for Moderna's stock.
• Investors are likely approaching Moderna's stock with caution due to uncertainties surrounding its revenue sources and future profitability.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna observed a downward trend in its stock price today despite investor confidence in its pandemic-related value. Possible reasons for this decline include:
• Decreased demand for Covid vaccines and regulatory challenges impacting investor optimism.
• Moderna faces uncertainties regarding its future trajectory and the viability of potential trading strategies related to the "hantavirus."
• News of Dominari Holdings' strong Q1 revenue growth and Sinovac Foundation's vaccine donations might have shifted investor focus away from Moderna, affecting its stock performance.
• Denison Mines' underwhelming earnings results and a poor financial health rating from InvestingPro could have contributed to negative overall market sentiment in the healthcare and biotech sectors, influencing Moderna's stock performance.

13.04.2026 - MRNA Stock was down 5.4%

• The stock of Moderna faced a downturn despite being acknowledged as a highly impactful company globally.
• Factors such as declining demand for COVID vaccines and a complex regulatory environment may have influenced the market's pessimistic view.
• Investors appear wary of Moderna's future trajectory, particularly as the company navigates critical decisions and places bets on a "hantavirus trade" to regain momentum.
• While Moderna has received acclaim for its mRNA technology innovations, current market sentiment seems more concerned with the company's present obstacles and uncertainties.